-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Editor’s note iNature is China’s largest academic official account.
It is jointly created by the doctoral team of Tsinghua University, Harvard University, Chinese Academy of Sciences and other units.
The iNature Talent Official Account is now launched, focusing on talent recruitment, academic progress, scientific research information, and interested parties.
Long press or scan the QR code below to follow us
.
iNature lung cancer is still the most common and deadly cancer in the world
.
Small cell lung cancer (SCLC) is the deadliest type of lung cancer, accounting for ~ 15% of the total number of lung cancers
.
SCLC is an aggressive high-grade neuroendocrine tumor characterized by short doubling time, rapid growth, and early metastasis and spread
.
Most patients with SCLC develop resistance quickly, and their 5-year survival rate is very low (5-6%)
.
The complex mechanisms behind widespread SCLC metastasis and recurrence need to be elucidated in order to extend the lasting benefits of chemotherapy and immunotherapy to more patients
.
On September 27, 2021, the Chinese Academy of Medical Sciences/Peking Union Medical College Hejie and Sun Nan jointly published an online newsletter titled "The landscape of m6A regulators in small cell lung cancer: molecular characteristics, immunoassay in Molecular Cancer (IF=27.
40).
-oncology features, and clinical relevance" research paper, this study describes for the first time the abnormal expression pattern, specific immuno-oncology features, and clinical relevance of m6A regulatory factors in SCLC
.
The comprehensive evaluation of m6A modulators in SCLC will help to enhance the understanding of tumorigenesis and remodeling of the tumor immune microenvironment (TIME), and allow more effective chemotherapy and immunotherapy options
.
Lung cancer remains the most common and deadly cancer in the world
.
Small cell lung cancer (SCLC) is the deadliest type of lung cancer, accounting for ~ 15% of the total number of lung cancers
.
SCLC is an aggressive high-grade neuroendocrine tumor characterized by short doubling time, rapid growth, and early metastasis and spread
.
Most patients with SCLC develop resistance quickly, and their 5-year survival rate is very low (5-6%), even with a good initial response to standard chemotherapy
.
The addition of immune checkpoint inhibitors to conventional chemotherapy for small cell lung cancer is promising; however, their absolute long-term benefits are moderate
.
The complex mechanisms behind widespread SCLC metastasis and recurrence need to be elucidated in order to extend the lasting benefits of chemotherapy and immunotherapy to more patients
.
N6-methyladenosine (m6A) is the most abundant and common RNA modification in eukaryotic RNA and an important part of cancer biology
.
m6A modification (similar to other epigenetic modifications) is a dynamic and reversible process that is regulated by methyltransferases, RNA binding proteins, and demethylases
.
More and more evidences strongly indicate that m6A modification is a new determinant of tumor metastasis, recurrence and treatment resistance, especially anti-PD-1/PD-L1 monotherapy resistance
.
It has been proved that a variety of epigenetic abnormalities are closely related to the cancerous phenotype and aggressiveness of SCLC
.
However, as the most common RNA epigenetic modification, m6A has never been associated with SCLC progression
.
This is the first characterization of m6A regulatory factors—including their molecular characteristics, immuno-oncology characteristics, and clinical relevance
.
The research data highlights the importance of m6A modulators to the pathogenesis of cancer and the formation of tumor immune microenvironment (TIME), and lays a reasonable foundation and support for the development of m6A-modified therapeutic strategies for SCLC patients
.
Reference message: https://molecular-cancer.
biomedcentral.
com/articles/10.
1186/s12943-021-01408-5
It is jointly created by the doctoral team of Tsinghua University, Harvard University, Chinese Academy of Sciences and other units.
The iNature Talent Official Account is now launched, focusing on talent recruitment, academic progress, scientific research information, and interested parties.
Long press or scan the QR code below to follow us
.
iNature lung cancer is still the most common and deadly cancer in the world
.
Small cell lung cancer (SCLC) is the deadliest type of lung cancer, accounting for ~ 15% of the total number of lung cancers
.
SCLC is an aggressive high-grade neuroendocrine tumor characterized by short doubling time, rapid growth, and early metastasis and spread
.
Most patients with SCLC develop resistance quickly, and their 5-year survival rate is very low (5-6%)
.
The complex mechanisms behind widespread SCLC metastasis and recurrence need to be elucidated in order to extend the lasting benefits of chemotherapy and immunotherapy to more patients
.
On September 27, 2021, the Chinese Academy of Medical Sciences/Peking Union Medical College Hejie and Sun Nan jointly published an online newsletter titled "The landscape of m6A regulators in small cell lung cancer: molecular characteristics, immunoassay in Molecular Cancer (IF=27.
40).
-oncology features, and clinical relevance" research paper, this study describes for the first time the abnormal expression pattern, specific immuno-oncology features, and clinical relevance of m6A regulatory factors in SCLC
.
The comprehensive evaluation of m6A modulators in SCLC will help to enhance the understanding of tumorigenesis and remodeling of the tumor immune microenvironment (TIME), and allow more effective chemotherapy and immunotherapy options
.
Lung cancer remains the most common and deadly cancer in the world
.
Small cell lung cancer (SCLC) is the deadliest type of lung cancer, accounting for ~ 15% of the total number of lung cancers
.
SCLC is an aggressive high-grade neuroendocrine tumor characterized by short doubling time, rapid growth, and early metastasis and spread
.
Most patients with SCLC develop resistance quickly, and their 5-year survival rate is very low (5-6%), even with a good initial response to standard chemotherapy
.
The addition of immune checkpoint inhibitors to conventional chemotherapy for small cell lung cancer is promising; however, their absolute long-term benefits are moderate
.
The complex mechanisms behind widespread SCLC metastasis and recurrence need to be elucidated in order to extend the lasting benefits of chemotherapy and immunotherapy to more patients
.
N6-methyladenosine (m6A) is the most abundant and common RNA modification in eukaryotic RNA and an important part of cancer biology
.
m6A modification (similar to other epigenetic modifications) is a dynamic and reversible process that is regulated by methyltransferases, RNA binding proteins, and demethylases
.
More and more evidences strongly indicate that m6A modification is a new determinant of tumor metastasis, recurrence and treatment resistance, especially anti-PD-1/PD-L1 monotherapy resistance
.
It has been proved that a variety of epigenetic abnormalities are closely related to the cancerous phenotype and aggressiveness of SCLC
.
However, as the most common RNA epigenetic modification, m6A has never been associated with SCLC progression
.
This is the first characterization of m6A regulatory factors—including their molecular characteristics, immuno-oncology characteristics, and clinical relevance
.
The research data highlights the importance of m6A modulators to the pathogenesis of cancer and the formation of tumor immune microenvironment (TIME), and lays a reasonable foundation and support for the development of m6A-modified therapeutic strategies for SCLC patients
.
Reference message: https://molecular-cancer.
biomedcentral.
com/articles/10.
1186/s12943-021-01408-5
